V.I. Technologies, Inc. Secures $20 Million in Private Placement Financing

Strategic Insights -

V.I. Technologies, Inc. (VITX) has secured a significant influx of capital through a private placement of its common stock and warrants, totaling $20 million. The funding, led by Great Point Partners LLC, marks a major milestone for the biotechnology company, which is developing anti-infective products. The private placement is designed to close simultaneously with the merger between VITX and Panacos Pharmaceuticals Inc., a key partner in the biotech sector.

Key Takeaways:

  • The $20 million private placement will be used to fund VITX's operations and development of its anti-infective products, including the Inactine technology, which inactivates a range of viruses and bacteria.
  • The financing is led by Great Point Partners LLC, with investors from Panacos Pharmaceuticals Inc., including Ampersand Ventures and A.M. Pappas and Associates, participating in the financing.
  • VITX will issue 100,000,000 shares of common stock at an effective price of $0.20 per share and detachable warrants to purchase up to 45,000,000 shares of common stock at $0.24 per share exercisable over 5 years.
  • The private placement investors will have the right to appoint a member to VITX's board of directors, which will continue to have a majority of independent directors.
  • VITX has also announced a restructuring of its operations to reduce expenses, including an immediate reduction in the company's workforce by approximately 40%.
  • Panacos Pharmaceuticals has initiated a phase 2a clinical trial of its HIV drug candidate, PA-457, with the goal of completing dosing of all patients and reporting preliminary results in the first half of 2005.

Statistics:

  • $20 million: The total amount raised through the private placement of VITX's common stock and warrants.
  • 100,000,000 shares: The number of common shares of VITX that will be issued to investors.
  • 45,000,000 shares: The maximum number of common shares that can be purchased by investors using the detachable warrants.
  • $0.20 per share: The effective price of the common shares issued in the private placement.
  • $0.24 per share: The exercise price of the detachable warrants.
  • 5 years: The exercise period for the detachable warrants.
  • Approximately 40%: The reduction in workforce at VITX as part of its restructuring efforts.

Sources:

  • Health & Medicine Week, 2005.
  • V.I. Technologies, Inc.
  • Panacos Pharmaceuticals Inc.
  • Great Point Partners LLC.
  • Ampersand Ventures.
  • A.M. Pappas and Associates.